Abstract
Crizotinib is an ATP-competitive small-molecule inhibitor of the receptor tyrosine kinases (RTK) c-Met, anaplastic lymphoma kinase (ALK), and ROS1. There is convincing clinical evidence for the effectiveness in non-small-cell lung cancer (NSCLC) harboring EML4-ALK rearrangements resulting in constitutional activation of the ALK-RTK. The drug is approved for this entity, which represents no more than 3–5 % of all NSCLC. However, in this population, impressive response rates are generated. The same seems to be true for ROS-1 rearrangements; however, these only occur in approximately 1 % of all NSCLC. The role in c-Met altered cancers needs to be determined. Toxicities include visual impairment, nausea, peripheral edema, QT-prolongation, and liver enzyme elevation. Also, the occurrence of renal cysts is reported. Fluorescence in situ hybridization (FISH) detecting the ALK rearrangement has to be performed on tumor tissue to predict crizotinib efficacy. The role of immunohistochemistry in this setting needs to be determined. It has high concordance with FISH results when strongly positive or completely negative. The high efficacy of crizotinib in ALK- and ROS-positive lung cancer as new molecular targets beside the epidermal growth factor receptor (EGFR) underscores the importance of molecular typing in NSCLC.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13(10):1011–1019
Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18):1734–1739
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6(12):3314–3322
Cilloni D, Carturan S, Bracco E, Campia V, Rosso V, Torti D et al (2013) Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Leuk Res 37(5):520–530
Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W et al (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29(15):e443–e445
Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung PP, Pairish M et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54(18):6342–6363
Curran MP (2012) Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs 72(1):99–107
Fleuren ED, Roeffen MH, Leenders WP, Flucke UE, Vlenterie M, Schreuder HW et al (2013) Expression and clinical relevance of MET and ALK in Ewing sarcomas. Int J Cancer 133(2):427–436
Hirsch FR, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R et al (2013) Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 8(3):373–384
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703
Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY et al (2013) Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 119(9):1627–1635
Matthay KK, George RE, Yu AL (2012) Promising therapeutic targets in neuroblastoma. Clin Cancer Res 18(10):2740–2753
Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H et al (2012) Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 11(7):1557–1564
Ordemann R, Stohlmacher J, Beuthien-Baumann B, Platzek I, van den Hoff J, Kroschinsky F et al (2013) Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. Ann Hematol 92(1):125–127
Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW et al (2011) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6(5):942–946
Ou SH, Bang YJ, Camidge DR, Riely G (2013) Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cll lung cancer (NSCLC). J Clin Oncol 31:8032
Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH et al (2012) Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77(2):288–292
Rodig SJ, Shapiro GI (2010) Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Invest Drugs 11(12):1477–1490
Salgia R, Solomon B, Shaw AT, Camidge DR (2011) Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) treated with crizotinib. J Clin Oncol 30:7596
Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L et al (2010) The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 70(24):10038–10043
Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004–1012
Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ et al (2013a) Crizotinib versus Chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394
Shaw AT, Mehra R, Kim DW, Felip E (2013b) Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 31(suppl), abstr 8010. 2013
Takeda M, Okamoto I, Nakagawa K (2013) Clinical impact of continued Crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 8(5):654–657
Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H et al (2011) MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 6(10):1624–1631
Tothova Z, Wagner AJ (2012) Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. Curr Opin Oncol 24(4):409–413
Xalkori (crizotinib) prescribing information. Pfizer Inc. 2012
Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB (2012) Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 7(7):1086–1090
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67(9):4408–4417
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Heigener, D.F., Reck, M. (2014). Crizotinib. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54490-3_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-54490-3_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54489-7
Online ISBN: 978-3-642-54490-3
eBook Packages: MedicineMedicine (R0)